Rein Therapeutics releases corporate presentation on LTI-03 idiopathic pulmonary fibrosis program

The pipeline update flagged LTI-01 for loculated pleural effusions as Phase 2b-ready, with development temporarily delayed to prioritize LTI-03.

Rein Therapeutics highlighted lead inhaled peptide LTI-03 for idiopathic pulmonary fibrosis, now in Phase 2 with an interim readout expected in 2026.

Phase 1b met its primary endpoint; high-dose 5 mg twice daily was well tolerated with no identified safety issues.

The program showed biomarker shifts linked to lung health, including a 5% decrease in surfactant protein D over two weeks at 5 mg.

Management framed LTI-03 as a multi-pathway caveolin-1 scaffolding domain mimic with antifibrotic activity, alongside signals of epithelial cell support.